X

Trial Profile

An Open Label Trial of TMC114/RTV in HIV-1 Infected Treatment Experienced Subjects.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Jul 2014

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Darunavir (Primary) ; Ritonavir (Primary) ; Antiretrovirals; HIV protease inhibitors
Indications HIV-1 infections
Focus Registrational; Therapeutic Use
Acronyms POWER-3
Sponsors Janssen R&D Ireland

Most Recent Events

12 May 2009 Planned number of patients changed from 450 to 555 as reported by ClinicalTrials.gov.
12 May 2009 Planned number of patients changed from 450 to 555 as reported by ClinicalTrials.gov.
12 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com